Related Experiment Video
Updated: Feb 27, 2026
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
Published on: December 14, 2017
Membrane Dysfunction as a Central Mechanism in LRRK2-Associated Parkinson's Disease: Comparative Analysis of G2019S
Khushboo Singh1, Roon Banerjee1, Chandrakanta Potdar1
1Department of Biophysics, National Institute of Mental Health and Neurosciences, Institute of National Importance, Bengaluru 560029, Karnataka, India.
Abstract:
Mutations in leucine-rich repeat kinase 2 (LRRK2) are among the most common genetic causes of Parkinson's disease (PD), yet substantial heterogeneity exists among pathogenic variants. How mutations in distinct functional domains of LRRK2 differentially perturb cellular homeostasis remains incompletely understood. Here, we compared two pathogenic LRRK2 mutations-G2019S in the kinase domain and I1371V in the GTPase domain-across multiple cellular models, including SH-SY5Y and U87 cells, and healthy human iPSC-derived floor plate cells. We demonstrate that the I1371V mutation induces markedly more severe cellular dysfunction than G2019S. I1371V-expressing cells exhibited elevated LRRK2 autophosphorylation at S1292 and robust hyperphosphorylation of Rab8A and Rab10, indicating enhanced downstream signaling. These alterations impaired sterol trafficking, leading to selective depletion of membrane cholesterol without changes in total cellular cholesterol. Consequently, I1371V cells displayed increased membrane fluidity, disrupted microdomain organization, altered membrane topology, reduced caveolin-1 expression, and impaired dopamine transporter surface expression and dopamine uptake. Lipidomic profiling further revealed a broad disruption of lipid homeostasis, including reductions in cholesteryl esters, sterols, sphingolipids, and glycerophospholipids, whereas G2019S cells showed comparatively modest changes. Pharmacological intervention revealed mutation-specific responses, with the non-selective LRRK2 modulator GW5074 outperforming the kinase-selective inhibitor MLi-2 in restoring Rab8A phosphorylation, membrane integrity, and dopaminergic function. Collectively, these findings identify membrane lipid dysregulation as a central cell biological mechanism in LRRK2-associated PD and underscore the importance of variant-specific therapeutic strategies.
Insights
Leucine-rich repeat kinase 2 (LRRK2) mutations cause Parkinson's disease (PD). The I1371V variant severely disrupts cellular lipid homeostasis and membrane function more than G2019S, indicating variant-specific therapeutic needs.
Area of Science:
- Neuroscience
- Genetics
- Cell Biology
Background:
- Mutations in leucine-rich repeat kinase 2 (LRRK2) are a leading genetic cause of Parkinson's disease (PD).
- Significant heterogeneity exists among pathogenic LRRK2 variants, impacting cellular function differently.
- The precise mechanisms by which distinct LRRK2 mutations perturb cellular homeostasis are not fully understood.
Purpose of the Study:
- To compare the cellular effects of two pathogenic LRRK2 mutations: G2019S (kinase domain) and I1371V (GTPase domain).
- To investigate how these mutations differentially affect cellular homeostasis, lipid trafficking, and membrane integrity.
- To explore mutation-specific responses to pharmacological interventions for potential therapeutic strategies.
Main Methods:
- Comparative analysis of LRRK2 mutations G2019S and I1371V in cellular models (SH-SY5Y, U87, iPSC-derived floor plate cells).
- Assessment of LRRK2 autophosphorylation, Rab8A/Rab10 phosphorylation, sterol trafficking, membrane properties (fluidity, topology), and dopamine transporter function.
- Lipidomic profiling and evaluation of pharmacological interventions (GW5074, MLi-2).
Main Results:
- The I1371V mutation induced more severe cellular dysfunction than G2019S, including elevated LRRK2 and Rab phosphorylation.
- I1371V impaired sterol trafficking, leading to selective membrane cholesterol depletion, increased membrane fluidity, and disrupted microdomains.
- Lipidomic analysis revealed broad lipid homeostasis disruption in I1371V cells, with modest changes in G2019S cells; pharmacological treatments showed mutation-specific efficacy.
Conclusions:
- Membrane lipid dysregulation is a key mechanism in LRRK2-associated Parkinson's disease.
- The I1371V mutation profoundly impacts cellular membrane integrity and function.
- Therapeutic strategies for LRRK2 Parkinson's disease should consider the specific mutation and its distinct cellular consequences.
Related Concept Videos
01:22Lysosomal Hydrolases
01:15Parkinson's Disease: Overview
01:37Neural Regulation